Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma sells 260,001 shares to non-U.S. investor for $650,002.50

Neutral Impact 2 of 5 financing Written later

Liminatus Pharma agreed on November 2, 2026 to sell 260,001 common shares at $2.50 each in a private placement to a non-U.S. investor, raising gross proceeds of $650,002.50. The company plans to use the proceeds for working capital and general corporate purposes, with closing expected on or about November 20, 2026. The company also agreed to file a resale registration statement within 60 days of closing, which could add shares that may be sold into the market later.

Key points

  • Shares: 260,001 common shares at $2.50 per share
  • Gross proceeds: $650,002.50, for working capital and general corporate purposes
  • Expected closing: on or about November 20, 2026
  • Company must file a resale registration statement with the SEC within 60 days of closing

The filing

CompanyLiminatus Pharma, Inc. (LIMN)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:15 PM ET
Accession number0001104659-26-122012

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.